Company
UltraSight
Ness Ziona, Israel-founded company, grown out of research connected to NYU and the Weizmann Institute. Builds AI software that guides non-sonographers through diagnostic-quality cardiac ultrasound scans on ultrasound hardware hospitals already own.
1 story
Regulatory News has published 1 story about UltraSight on 4 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 4 October 2026.
This page is generated from Regulatory News’ editorial coverage of UltraSight. It is not an advertisement.
On the record
- Company
- UltraSight Ltd.
- Headquarters
- Ness Ziona, Israel
- Founded
- 2018, growing out of research connected to NYU and the Weizmann Institute's Yeda Research and Development
- Regulator
- U.S. Food and Drug Administration (AI Guidance software cleared under 510(k) K223347 and K251416)
- Latest milestone
- $24 million Series B2 financing
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
